Health Canada

Canada launches new toll-free 1-844 POISON-X number for poison centres

Retrieved on: 
Tuesday, March 21, 2023
Learning, Accidental, Analgesic, National Poisons Information Service, Injury, University, Ipsos, Parachute, Poisoning, Parent, Health Canada, Government, Plasma protein binding, Evidence, Hospital, Child, National Poison Prevention Week, Cannabis, Government of Canada, Ageing, Poison, Death, Mushroom, Health insurance, Tutoring

Unfortunately, while there are currently nine different phone numbers used to access the five poison centres in Canada, many Canadians don't know the phone number for their local poison centre or even that the service is available.

Key Points: 
  • Unfortunately, while there are currently nine different phone numbers used to access the five poison centres in Canada, many Canadians don't know the phone number for their local poison centre or even that the service is available.
  • For this reason, Health Canada has launched a new toll-free number, 1-844 POISON-X, or 1-844-764-7669, in collaboration with four Canadian poison centres, to make it easier for people in Canada to access critical medical advice for poisonings.
  • By calling this number, Canadians will now be re-routed to their local poison centre regardless of where they are calling from in the country.
  • "A single toll-free number to access the essential services of poison centres across Canada has been a long time coming and has been the vision of the Canadian Association of Poison Centres and Clinical Toxicology for over 20 years.

Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

Retrieved on: 
Saturday, March 18, 2023
DIN, Sodium chloride, Sepsis, Abscess, Health status of Asian Americans, Urinary tract infection, Pharmacy, Patient, Risk, Cystic fibrosis, Health, Health Canada, Glass, Pneumonia, Pharmaceutical industry, Medical device, Aztreonam

Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots (032168 and 033357) of the cystic fibrosis drug Cayston (aztreonam) (DIN 02329840) on March 1, 2023 , due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.

Key Points: 
  • Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots (032168 and 033357) of the cystic fibrosis drug Cayston (aztreonam) (DIN 02329840) on March 1, 2023 , due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.
  • A cracked glass vial could cause potential injury or lead to potential contamination or a reduced dose.
  • Cayston is a prescription antibacterial medicine used for the management of chronic infections in cystic fibrosis patients.
  • The manufacturer has not received any customer complaints in relation to cracked glass vials in the recalled lots, or any other Cayston lots distributed in Canada.

EQS-News: TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

Retrieved on: 
Friday, March 17, 2023
Magnet, Infection, CE, TVM, Radiation, PFC, Therapy, Partnership, Workflow, Pathology, CAD, General partnership, Sleep apnea, Partner (business rank), Science, Creativity, II, Knee pain, Thrombosis, Motion, Phlebitis, Investment, Risk, Patient, LSI, Growth, Eli Lilly and Company, Eye injury, AI, FDA, Health Canada, Summit, Knee, Pharmaceutical industry, Renewable energy, Medical imaging, Medical device, EU

Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 20-23, 2023, in Dana Point, California, USA.
  • “Medtech innovation plays a pivotal role in the healthcare ecosystem and has the potential to revolutionize the industry by improving patient outcomes, increasing efficiency, and reducing costs.
  • One key component of our strategy is to invest in disruptive, breakthrough, commercial-stage technologies that map essential future trends and significantly transform current standard-of-care.

TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

Retrieved on: 
Friday, March 17, 2023
Magnet, Infection, CE, TVM, Radiation, PFC, Therapy, Partnership, Workflow, Pathology, CAD, General partnership, Sleep apnea, Partner (business rank), Science, Creativity, II, Knee pain, Thrombosis, Motion, Phlebitis, Investment, Risk, Patient, LSI, Growth, Eli Lilly and Company, Eye injury, AI, FDA, Health Canada, Summit, Knee, Pharmaceutical industry, Renewable energy, Medical imaging, Medical device, EU

MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 20-23, 2023, in Dana Point, California, USA.
  • “Medtech innovation plays a pivotal role in the healthcare ecosystem and has the potential to revolutionize the industry by improving patient outcomes, increasing efficiency, and reducing costs.
  • One key component of our strategy is to invest in disruptive, breakthrough, commercial-stage technologies that map essential future trends and significantly transform current standard-of-care.

Jones Healthcare Group Primed to Help Nutraceutical Brands Comply with New Canadian Packaging Regulations

Retrieved on: 
Thursday, March 16, 2023
Health, Health Canada, Bobst, Gallus, Uhlmann, AVT, Pressure, UV, Koenig & Bauer

Investment in Label Press Expands Packaging Offering to Support Extended Content Requirements

Key Points: 
  • London, Ontario--(Newsfile Corp. - March 16, 2023) - Jones Healthcare Group, a market leader in advanced packaging and medication dispensing solutions, is poised to support nutraceutical brands ahead of new packaging regulations for products sold in Canada.
  • The new press expands Jones Healthcare's extended content packaging offering, which helps brands include significantly more product information required by these regulations from Health Canada .
  • Jones Healthcare has extensive experience supporting clients with these regulations, which came into force for over-the-counter drug products in previous years.
  • The Jones Healthcare Group team is ready to help nutraceutical brands comply to new packaging regulations with the installation of a Gallus Labelmaster 440 pressure sensitive label press from HEIDELBERG.

Public advisory - Robikids and Solmux are unauthorized children's syrups for thinning mucus and may pose serious health risks

Retrieved on: 
Thursday, March 16, 2023
Health Canada, Health, NPN, Sale, Caregiver, Nausea, Stomach, Gastrointestinal bleeding, Diarrhea, Anaphylaxis, Pharmacy, Drug identification number, Plasma protein binding, Patient, Allergy, Heartburn, History, Tropical ulcer, Prescription drug, Natural product, Safety, Child, Parent, Mucus, Carbocisteine, DIN, Nonsteroidal anti-inflammatory drug, ASA, Dietary supplement

Health Canada is warning parents and caregivers about two unauthorized children's syrups for thinning mucus, Robikids and Solmux, seized from Kamshoppe, which advertised the products on Facebook.

Key Points: 
  • Health Canada is warning parents and caregivers about two unauthorized children's syrups for thinning mucus, Robikids and Solmux, seized from Kamshoppe, which advertised the products on Facebook.
  • Both products are labelled to contain carbocisteine, a prescription drug that may pose serious health risks such as nausea, diarrhea, allergic reactions (e.g., anaphylaxis) and gastrointestinal bleeding.
  • Should Health Canada identify other distributors or retailers of these unauthorized health products, it will take action and inform the public as appropriate.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.

iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, March 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Genetics, Other Health, Assistant, OvaScience, ACOG, Baystate Health, Gene editing, Phenylketonuria, Bangladesh Technical Education Board, University of Massachusetts Amherst, Isenberg School of Management, Health Canada, Tufts University School of Medicine, PKU, Patient, American College, Medical director, FACMG, MBA, Food and Drug Administration, DSM-IV codes, FDA, CMO, Obstetrics and gynaecology, SUNY, Growth, State University of New York Upstate Medical University, Medical genetics, Food, Therapy, IND, Drug, OTC, University, Liver, Pharmaceutical industry, Genomics, Gynaecology, Obstetrics

iECURE , a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, today announced the appointment of Gabriel M. Cohn, M.D., MBA as Chief Medical Officer.

Key Points: 
  • iECURE , a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, today announced the appointment of Gabriel M. Cohn, M.D., MBA as Chief Medical Officer.
  • “Gabe’s experience in clinical development as a CMO will be crucial as we begin the process of global regulatory submissions and patient dosing.
  • from SUNY Health Science Center at Syracuse and MBA from the Isenberg School of Management at the University of Massachusetts Amherst.
  • He completed a residency in Obstetrics & Gynecology at SUNY HSC at Syracuse and a fellowship in Medical Genetics at the National Institutes of Health.

Isologic Launches Illuccix® PSMA PET Imaging Agent to Detect Prostate Cancer

Retrieved on: 
Thursday, March 16, 2023
Health Canada, Cancer, Physician, Health, Prostate cancer, Hope, PSMA, Patient, Medical imaging, Isolog schools

MONTREAL, March 16, 2023 /CNW/ - Isologic Innovative Radiopharmaceuticals is proud to announce that the prostate cancer imaging agent Illuccix®, Ga 68 Gozetotide Preparation Kit, also known as PSMA-11, is now available in Canada.

Key Points: 
  • MONTREAL, March 16, 2023 /CNW/ - Isologic Innovative Radiopharmaceuticals is proud to announce that the prostate cancer imaging agent Illuccix®, Ga 68 Gozetotide Preparation Kit, also known as PSMA-11, is now available in Canada.
  • 24,000 men are diagnosed with prostate cancer each year in Canada, making it the number one cancer among men.
  • "Health Canada has approved Illuccix®, providing Canadian physicians with a new diagnostic tool" states André Gagnon, president of Isologic.
  • "Illuccix® is a valuable tool to help physicians detect metastatic prostate cancer and guide patient management decisions.

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

Retrieved on: 
Wednesday, March 15, 2023
Annual report, Acquisition, Table, Three Months, AAT, Webcast, International, Plasma, Pivotal, TASE, Regulation of tobacco by the U.S. Food and Drug Administration, Health Canada, St Saviour's and St Olave's Church of England School, Depreciation, R, KMDA, Immunoglobulin G, EBITDA, Acceleration, Investment, FDA, DSMB, Globalization, G&A, European Medicines Agency, Growth, Internet, Security (finance), Safety, Innova (video game company), Food, S&M, Video game, Cryptocurrency, Rare-earth element, Pharmaceutical industry, Fine chemical, Reinsurance, Insurance, Takeda, Kamada

“Importantly, we expect the momentum from 2022 to extend throughout 2023, with profitability to be further enhanced.

Key Points: 
  • “Importantly, we expect the momentum from 2022 to extend throughout 2023, with profitability to be further enhanced.
  • As such, we are introducing full-year 2023 revenue guidance of $138 million to $146 million and EBITDA guidance of $22 million to $26 million.
  • Total revenues during the fourth quarter of 2022 included strong sales from the portfolio of four acquired FDA-approved IgG products.
  • Adjusted EBITDA, as detailed in the tables below, was $7.2 million in the fourth quarter of 2022, as compared to ($1.3) million in the fourth quarter of 2021.

Kardium Announces First Patients Treated in PULSAR IDE Study of Globe® Pulsed Field System

Retrieved on: 
Wednesday, March 15, 2023
Health, Clinical Trials, Medical Devices, Atrial fibrillation, Heart, Sale, PFA, Health Canada, Mount Sinai Hospital (Manhattan), Trial of the century, PULSE, Czech Republic, Patient, FRCPC, AF, McGill University Health Centre, Food and Drug Administration, FDA, Mount Sinai Hospital, PVI, Gold, Electrode, Safety, Femoral vein, McGill University, IDE, Inc., Food, Associate professor, Medical device, Nursing, MD, Globe

Kardium Inc. , a private medical device company that has developed the Globe® PF System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today that the first patients have been successfully treated in its PULSAR clinical study.

Key Points: 
  • Kardium Inc. , a private medical device company that has developed the Globe® PF System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today that the first patients have been successfully treated in its PULSAR clinical study.
  • The PULSAR study will enroll over 400 patients for treatment at up to 35 sites in the United States, Canada, and Europe.
  • The study expands on the successful Globe System first-in-human trial (PULSE-EU) of 69 patients.
  • “The PULSAR study will expand our knowledge in the exciting and rapidly developing field of PF.”
    “The whole team at Kardium is thrilled to be starting the PULSAR study,” said Kardium CEO Kevin Chaplin.